华恒生物(688639) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 500,781,373.59, representing a year-on-year increase of 25.12%[4] - The net profit attributable to shareholders for Q1 2024 was RMB 86,574,111.12, reflecting a year-on-year increase of 6.62%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 85,910,725.23, with a year-on-year increase of 9.70%[4] - The basic earnings per share for Q1 2024 was RMB 0.55, with a year-on-year increase of 5.77%[5] - The net profit for Q1 2024 was 85,868,603.65, an increase from 81,188,337.13 in Q1 2023, representing a growth of approximately 8.3%[18] - The total comprehensive income for Q1 2024 was 85,891,665.47, compared to 81,188,337.13 in Q1 2023, representing an increase of approximately 5.5%[18] Assets and Liabilities - The total assets at the end of Q1 2024 amounted to RMB 4,387,222,058.02, an increase of 10.50% compared to the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to RMB 1,208,314,144.17, up from RMB 1,050,046,406.02 as of December 31, 2023, indicating a growth of approximately 15%[13] - The total assets reached RMB 4,387,222,058.02, compared to RMB 3,970,238,093.30 at the end of 2023, marking an increase of approximately 10.5%[15] - The total liabilities increased to RMB 2,485,453,279.91 from RMB 2,144,577,318.12, which is an increase of around 15.9%[15] - The company’s non-current assets totaled RMB 3,178,907,913.85, an increase from RMB 2,920,191,687.28, reflecting a growth of approximately 8.8%[14] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative RMB 103,415,745.55, indicating a significant decrease of 212.66% due to increased inventory for new product launches[8] - The net cash flow from operating activities for Q1 2024 was -103,415,745.55, a decline from 91,795,730.89 in Q1 2023, indicating a significant decrease[20] - Cash inflow from investment activities totaled $2,748,300, a significant decrease from$253,204,502 in the previous period[21] - Cash outflow from investment activities amounted to $201,073,326, resulting in a net cash flow from investment activities of -$198,325,026.45, compared to -$66,009,054.97 previously[21] - Cash inflow from financing activities reached$459,077,480.64, up from $113,947,653.82 in the prior period[21] - Net cash flow from financing activities was$316,603,710.53, compared to $113,947,653.82 previously[21] - The net increase in cash and cash equivalents was$17,932,110.04, a decrease from $139,683,066.02 in the previous period[21] - The ending balance of cash and cash equivalents was$370,426,208.82, compared to $286,656,669.32 previously[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,631[10] - The largest shareholder, Guo Henghua, held 31,191,000 shares, representing 19.80$459,077,480.64, compared to $113,947,653.82 in the previous period[21] - Cash paid for debt repayment was$119,719,401.18, with cash paid for dividends and interest amounting to $10,391,961.39[21] - The impact of exchange rate changes on cash and cash equivalents was$3,069,171.51, compared to -$51,263.72 previously[21] - The company did not apply new accounting standards or interpretations starting in 2024[21]